The Analyst Landscape: 4 Takes On Aclaris Therapeutics
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) has received mixed ratings from 4 analysts in the last three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is now $5.25, a significant drop from the previous $21.67. Analysts from HC Wainwright & Co. and Stifel have maintained and lowered their price targets, respectively, reflecting changes in market dynamics and company performance. Aclaris is a clinical-stage biopharmaceutical company with a focus on immuno-inflammatory diseases. Financially, the company has seen a -51.19% decline in revenue growth and has a net margin of -315.24%, with an ROE of -17.41% and an ROA of -12.89%. The company has no debt with a debt-to-equity ratio of 0.0.
January 11, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aclaris Therapeutics has received mixed analyst ratings and a significant reduction in the average price target, indicating potential concerns about the company's future performance. The company's financials show a substantial revenue decline and negative profitability metrics, which may impact investor sentiment.
The sharp decrease in the average price target and the negative financial indicators such as the significant revenue decline and poor profitability metrics (net margin, ROE, ROA) suggest that there may be a negative short-term impact on ACRS's stock price. The unanimous reduction in price targets by analysts from reputable firms further supports the likelihood of a negative impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100